HeartWRAP: Advances in
Cardiovascular Medicine

Focus on Cardioselective Beta-Blockers
for Heart Failure & Hypertension

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

February 1, 2008

Expiration Date:

February 1, 2010

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties: Primary Care, Cardiologists, Hypertension Specialists, Internists with Cardiology Specialty Focus, Preventive Medicine Specialists, and Endocrinologists

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Forest Laboratories Inc

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Program Faculty:

Mark Dunlap, MD
Associate Professor of Medicine, Physiology and Biophysics
Case Western Reserve University
Director, Heart Failure Section
Heart and Vascular Center H3
MetroHealth Medical Center
Cleveland, OH

Faculty Disclosures:

Dr. Dunlap has received grant/research support from Astra Zeneca, NitroMed, Otsuka and Amgen. He has been a Consultant for Astra Zeneca, NitroMed, Bristol-Myers Squibb, Novartis, Forest Pharmaceuticals, Otsuka, and Amgen. He has served on the Speaker's Bureau for Astra Zeneca and NitroMed.

Educational Objectives:

• Practitioners will learn how to approach hypertension as a systematic disease, with multiple manifestations, and associations, including assessment of coexisting conditions that support use of specific classes or agents.
• Practitioners will learn about the complications linked to healthcare disparities observed in specific patient populations, and the importance of providing access, treatment, and monitoring of patients with multiple risk CV risk factors.
• Practitioners will learn how to manage complicated patients with high blood pressure, including those with ischemic heart disease and/or heart failure.
• Practitioners will learn the importance of early treatment of patients with high blood pressure, markers to look for, and the importance of treating both systolic and diastolic blood pressure abnormalities.
• Practitioners specialists will learn how to apply evidence-based and guideline-consistent management of hypertension to specific patient subgroups. Current clinical studies and trials will be reviewed and discussed in detail.
• Practitioners will learn about the safety profiles of antihypertensive agents across multiple patient risk groups.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright (c) 2007 All rights reserved